GlassScriptPhysician profile
Richard C Andersen
NPI 1467612267
$1,215.31
in general payments reported to CMS, 2019-2025
22 companies · $115 in 2025
The $115 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.95 · 2020: $71.34 · 2021: $332 · 2022: $271 · 2023: $246 · 2024: $111 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $472.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $488.13 | 2021-2024 | Ubrelvy, Linzess, Viberzi |
| Amgen INC. | $165.23 | 2019-2025 | Evenity |
| Pfizer INC. | $92.34 | 2022-2024 | |
| Novo Nordisk INC | $78.94 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $62.01 | 2021 | |
| Lilly USA, LLC | $44.85 | 2022-2025 | Zepbound, Mounjaro |
| Allergan, INC. | $35.77 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.27 | 2025 | Caplyta |
| Eisai INC. | $27.40 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $23.52 | 2021 | |
| Calliditas Therapeutics US INC. | $20.20 | 2025 | Tarpeyo |
| Viatris Specialty LLC | $16.82 | 2025 | Yupelri |
| Celgene Corporation | $14.73 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.70 | 2019 | |
| Abbott Laboratories | $13.82 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $13.32 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.15 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.00 | 2020 | |
| Novartis Pharmaceuticals Corporation | $11.56 | 2020 | |
| Vbi Vaccine (Delaware) INC. | $11.33 | 2022 | |
| Glaxosmithkline, LLC. | $11.12 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Andersen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.